Russell Investments Group Ltd. Raises Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Russell Investments Group Ltd. lifted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 88.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 638 shares of the medical instruments supplier’s stock after purchasing an additional 300 shares during the period. Russell Investments Group Ltd.’s holdings in ICU Medical were worth $99,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Harvest Fund Management Co. Ltd bought a new stake in shares of ICU Medical in the 4th quarter valued at about $33,000. Murphy & Mullick Capital Management Corp purchased a new position in ICU Medical during the fourth quarter valued at approximately $52,000. Venturi Wealth Management LLC raised its stake in ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock worth $82,000 after buying an additional 206 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in ICU Medical by 166.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 907 shares of the medical instruments supplier’s stock worth $140,000 after buying an additional 567 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in ICU Medical during the 4th quarter valued at $202,000. Institutional investors own 96.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. KeyCorp decreased their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, Raymond James set a $97.00 price objective on shares of ICU Medical in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ICU Medical currently has a consensus rating of “Moderate Buy” and an average price target of $162.67.

ICU Medical Trading Down 1.1 %

ICU Medical stock opened at $135.66 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock has a market cap of $3.34 billion, a PE ratio of -29.68 and a beta of 0.86. The stock has a 50-day moving average of $143.81 and a two-hundred day moving average of $158.07. ICU Medical, Inc. has a one year low of $95.44 and a one year high of $196.26.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.